Literature DB >> 30227108

Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease.

Ciarán P Kelly1, Mark H Wilcox2, Henning Glerup3, Nazimuddin Aboo4, Misoo C Ellison5, Karen Eves5, Mary Beth Dorr5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30227108     DOI： 10.1053/j.gastro.2018.06.080

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  4 in total

Review 1.  The interplay of Clostridioides difficile infection and inflammatory bowel disease.

Authors:  Kanika Sehgal; Devvrat Yadav; Sahil Khanna
Journal:  Therap Adv Gastroenterol       Date:  2021-05-30       Impact factor: 4.409

Review 2.  Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease.

Authors:  Rahul S Dalal; Jessica R Allegretti
Journal:  Curr Opin Gastroenterol       Date:  2021-07-01       Impact factor: 2.741

3.  Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Paul B Larkin; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2021-11-15       Impact factor: 5.325

Review 4.  Management of Clostridioides difficile infection in patients with inflammatory bowel disease.

Authors:  Sahil Khanna
Journal:  Intest Res       Date:  2020-08-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.